Apellis Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
Apellis Pharmaceuticals (Nasdaq: APLS) will present at the 4th Annual Evercore ISI HealthCONx Conference on December 2, 2021, at 8:00 a.m. ET. The presentation will be conducted in a virtual format and can be accessed via a live webcast on the company’s website. A replay of the event will be available for 90 days post-conference. Apellis is a global leader in complement therapies, focusing on innovative treatments for diseases related to the complement cascade in various fields, including hematology and neurology.
- None.
- None.
WALTHAM, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the 4th Annual Evercore ISI HealthCONx Conference on Thursday, December 2, 2021 at 8:00 a.m. ET. The conference will be held in a virtual meeting format.
The conference event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit www.apellis.com.
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
FAQ
When will Apellis Pharmaceuticals present at the Evercore ISI HealthCONx Conference?
How can I watch the Apellis Pharmaceuticals presentation?
How long will the webcast replay be available after the presentation?
What is Apellis Pharmaceuticals known for?